RXi Pharmaceuticals Corp. (RXII)

1.19
0.01 0.83
NASDAQ : Health Technology
Prev Close 1.20
Open 1.18
Day Low/High 1.15 / 1.20
52 Wk Low/High 1.12 / 7.70
Volume 39.19K
Avg Volume 314.00K
Exchange NASDAQ
Shares Outstanding 4.38M
Market Cap 5.34M
EPS -5.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results And Recent Corporate Highlights

RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results And Recent Corporate Highlights

- Extended cash runway by securing net proceeds of $4.2 million in April 2018

RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring

RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring

- RXI-109 is a self-delivering RNAi (sd-rxRNA®) compound that targets connective tissue growth factor (CTGF), a key regulator of fibrosis and scar formation.

BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding For Continued Development Of Sd-rxRNA Drug Candidate For The Treatment Of Spinal Cord Injury

BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding For Continued Development Of Sd-rxRNA Drug Candidate For The Treatment Of Spinal Cord Injury

Award based on accomplishment of 1-year milestones; Collaborator RXi Pharmaceuticals to receive a portion of the allotted funding

BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding For Continued Development Of Sd-rxRNA Drug Candidate For The Treatment Of Spinal Cord Injury

BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding For Continued Development Of Sd-rxRNA Drug Candidate For The Treatment Of Spinal Cord Injury

BioAxone BioSciences, Inc. announced today that, as part of a collaborative effort with RXi Pharmaceuticals Corporation (NASDAQ: RXII), it is the recipient of a grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of...

RXi Pharmaceuticals Announces Positive Results From Phase 2 Trial With Samcyprone™ For The Treatment Of Common Warts

- Study successfully meets its primary effectiveness objectives and its secondary safety and tolerability objectives.

RXi Pharmaceuticals Enters Into Material Transfer Agreement With Iovance Biotherapeutics To Study Its Self-Delivering RNAi Technology For The Advancement Of Immuno-Oncology Therapeutics With Iovance's Tumor Infiltrating Lymphocytes (TILs) For Solid Tumors

Synergies between RXi's self-delivering RNAi (sd-rxRNA®) therapeutic platform and Iovance's TIL cell therapy approach will be explored preclinically

RXi Pharmaceuticals To Present An Update On Its Clinical And Cosmetic Dermatology Programs At The International Investigative Dermatology Conference

RXi Pharmaceuticals To Present An Update On Its Clinical And Cosmetic Dermatology Programs At The International Investigative Dermatology Conference

Poster presentations will include data from the Company's Phase 2 study with RXI-109 for the reduction of hypertrophic scars, its Phase 2 study with Samcyprone™ for the treatment of cutaneous warts and the consumer testing program with its cosmetic product RXI-231 to improve the appearance of skin pigmentation.

Focused on Speculative Trading: RXII, BB, CASA

Focused on Speculative Trading: RXII, BB, CASA

We have this drifting action and uncorrelated action between stocks and the indices.

Market Players Continue to Look for Reasons to Buy Rather Than to Sell

Market Players Continue to Look for Reasons to Buy Rather Than to Sell

My biggest concern about the market continues to be a paucity of perky picks.

3 Stocks Under $10 to Trade for Breakouts

3 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks are within range of triggering breakout trades.

Insider Trading Alert - RXII, MA And SWN Traded By Insiders

Insider Trading Alert - RXII, MA And SWN Traded By Insiders

Stocks with insider trader activity include RXII, MA and SWN

RXi Pharmaceuticals (RXII) Is Strong On High Volume Today

RXi Pharmaceuticals (RXII) Is Strong On High Volume Today

Trade-Ideas LLC identified RXi Pharmaceuticals (RXII) as a strong on high relative volume candidate

The Trend Is Up

If you turn bearish now, you'll quickly find yourself in trouble.

Ratings Changes Today

Upgrades: CEB, DAC, FARM, GIG, JOEZ, LGND, QDEL, RGC, RLOC, VCO, WSH Downgrades: AWRE, BNNY, CALX, ETR, GTS, HUN, ICE, NTT, PLOW, RDY Initiations: RXII Read on to get TheStreet Quant Ratings' detailed report:

RXi Pharmaceuticals To Present At The 25th Annual ROTH Conference

RXi Pharmaceuticals To Present At The 25th Annual ROTH Conference

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, and...

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, and...

RXi Pharmaceuticals Announces Upcoming Presentations

RXi Pharmaceuticals Announces Upcoming Presentations

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals To Present At 15th Annual BIO CEO & Investor Conference

RXi Pharmaceuticals To Present At 15th Annual BIO CEO & Investor Conference

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces Completion Of Enrollment In Second Phase 1 Trial For RXI-109 Program

RXi Pharmaceuticals Announces Completion Of Enrollment In Second Phase 1 Trial For RXI-109 Program

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

TheStreet Quant Rating: E+ (Sell)